Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) issued its quarterly earnings data on Monday. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. The company earned $12.80 million during the quarter, compared to the consensus estimate of $13.56 million. Enanta Pharmaceuticals had a net margin of 32.59% and a return on equity of 11.31%. Enanta Pharmaceuticals’s revenue for the quarter was down 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.29 earnings per share.

Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 30.07 on Tuesday. The firm has a market capitalization of $572.38 million, a P/E ratio of 19.89 and a beta of 0.61. The stock’s 50 day moving average price is $25.74 and its 200-day moving average price is $24.02. Enanta Pharmaceuticals has a 12 month low of $20.39 and a 12 month high of $34.49.

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

A number of equities analysts recently commented on ENTA shares. JPMorgan Chase & Co. set a $26.00 price objective on shares of Enanta Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Enanta Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $26.29.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in Enanta Pharmaceuticals by 295.7% in the second quarter. BlackRock Inc. now owns 4,614 shares of the company’s stock worth $102,000 after buying an additional 3,448 shares during the last quarter. Riverhead Capital Management LLC boosted its position in Enanta Pharmaceuticals by 1,505.1% in the second quarter. Riverhead Capital Management LLC now owns 6,292 shares of the company’s stock worth $324,000 after buying an additional 5,900 shares during the last quarter. Highbridge Capital Management LLC bought a new position in Enanta Pharmaceuticals during the third quarter worth $215,000. Adams Diversified Equity Fund Inc. bought a new position in Enanta Pharmaceuticals during the second quarter worth $194,000. Finally, Texas Permanent School Fund boosted its position in Enanta Pharmaceuticals by 4.3% in the third quarter. Texas Permanent School Fund now owns 10,586 shares of the company’s stock worth $282,000 after buying an additional 439 shares during the last quarter. 65.40% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

5 Day Chart for NASDAQ:ENTA

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.